Circulating endothelial cells and tumor blood volume as predictors in lung cancer

被引：24

作者：

Wang, Jing ^{[1
]}

Xiao, Jianyu ^{[2
]}

Wei, Xiyin ^{[1
]}

Wang, Liuchun ^{[1
]}

Lin, Li ^{[1
]}

Liu, Zhujun ^{[1
]}

Wang, Xinyue ^{[1
]}

Sun, Baocun ^{[1
]}

Li, Kai ^{[1
]}

机构：

[1] Tianjin Med Univ, Canc Inst & Hosp, Tianjin Key Lab Canc Prevent & Therapy, Dept Thorac Oncol, Tianjin, Peoples R China

[2] Tianjin Med Univ, Canc Inst & Hosp, Tianjin Key Lab Canc Prevent & Therapy, Dept Radiol, Tianjin, Peoples R China

来源：

CANCER SCIENCE | 2013年 / 104卷 / 04期

关键词：

PROGENITOR CELLS; BREAST-CANCER; PACLITAXEL-CARBOPLATIN; NEOADJUVANT CHEMOTHERAPY; PERIPHERAL-BLOOD; SOLID TUMORS; THERAPY; ANGIOGENESIS; PERFUSION; CT;

D O I：

10.1111/cas.12097

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The current criteria for evaluating antiangiogenic efficacy is insufficient as tumor shrinkage occurs after blood perfusion decreases. Tumor blood volume (BV) in computed tomography perfusion imaging and circulating endothelial cells (CEC) might predict the status of angiogenesis. The present study aimed to validate their representation as feasible predictors in non-small-cell lung carcinoma (NSCLC). A total of 74 patients was categorized randomly into two arms undergoing regimens of vinorelbine and cisplatin (Navelbine and platinum [NP]) with rh-endostatin or single NP. The response rate, perfusion imaging indexes and activated CEC (aCEC) during treatment were recorded. Progression-free survival (PFS) was determined through follow up. Correlations among the above indicators, response and PFS were analyzed: aCEC increased significantly in cases of progressive disease after single NP chemotherapy (P=0.024). Tumor BV decreased significantly in cases with a clinical benefit in the combined arm (P=0.026), whereas inverse correlations existed between aCEC (post-therapeutic value minus the pre-therapeutic value) and PFS (P=0.005) and between BV and PFS (P=0.044); a positive correlation existed between aCEC and BV. Therefore, both aCEC and tumor BV can serve as predictors, and detection of both indicators can help evaluate the chemo-antiangiogenic efficacy in NSCLC more accurately. (Cancer Sci 2013; 104: 445-452)

引用

页码：445 / 452

页数：8

共 48 条

[1] Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients [J].

Ali, Arwa M. ;

Ueno, Takayuki ;

Tanaka, Sunao ;

Takada, Masahiro ;

Ishiguro, Hiroshi ;

Abdellah, Ashraf Z. ;

Toi, Masakazu .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (15) :2265-2272

[2] VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells [J].

Asahara, T ;

Takahashi, T ;

Masuda, H ;

Kalka, C ;

Chen, DH ;

Iwaguro, H ;

Inai, Y ;

Silver, M ;

Isner, JM .

EMBO JOURNAL, 1999, 18 (14) :3964-3972

[3] Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].

Beaudry, P ;

Force, J ;

Naumov, GN ;

Wang, A ;

Baker, CH ;

Ryan, A ;

Soker, S ;

Johnson, BE ;

Folkman, J ;

Heymach, JV .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3514-3522

[4] Perfusion CT in solid body-tumours part II. Clinical applications and future development [J].

Bellomi, M. ;

Viotti, S. ;

Preda, L. ;

D'Andrea, G. ;

Bonello, L. ;

Petralia, G. .

RADIOLOGIA MEDICA, 2010, 115 (06) :858-874

[5] CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: Initial experience [J].

Bellomi, Massimo ;

Petralia, Giuseppe ;

Sonzogni, Angelica ;

Zampino, Maria Giulia ;

Rocca, Andrea .

RADIOLOGY, 2007, 244 (02) :486-493

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7] Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies [J].

Bernaards, C. ;

Hegde, P. ;

Chen, D. ;

Holmgren, E. ;

Zheng, M. ;

Jubb, A. M. ;

Koeppen, H. ;

Scherer, S. J. ;

Chen, D. S. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[8]

Bertolini F, 2003, CANCER RES, V63, P4342

[9] Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy [J].

Bidard, F. -C. ;

Mathiot, C. ;

Degeorges, A. ;

Etienne-Grimaldi, M. -C. ;

Delva, R. ;

Pivot, X. ;

Veyret, C. ;

Bergougnoux, L. ;

de Cremoux, P. ;

Milano, G. ;

Pierga, J. -Y. .

ANNALS OF ONCOLOGY, 2010, 21 (09) :1765-1771

[10] CANCER Limitations of therapies exposed [J].

Casanovas, Oriol .

NATURE, 2012, 484 (7392) :44-46

← 1 2 3 4 5 →